Anti-infection chemical
Atovaquone is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia.
Atovaquone 50 mg
£308.00
Target: pneumocystis pneumonia, toxoplasmosis, malaria, and babesia
Chemical name: 1,4-Naphthalenedione, 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-
Formula: C22H19ClO3
Molecular weight: 366.84
Purity: 99.9 % (HPLC)
Solubility: 5 mg/mL (DMSO)
Size: 50 mg
Storage: 3 years -20°C powder, 2 years -80°C in solvent
In vitro: Atovaquone (atavaquone) is a chemical compound that belongs to the class of naphthalenes. Atovaquone is a hydroxy-1,4-naphthoquinone, an analog of ubiquinone, with antipneumocystic activity.[1] Atovaquone is an anti-protozoal mitochondrial electron transport inhibitor; Antimalarial; Antipneumocystic, and has also been used to treat toxoplasmosis. It acts by inhibiting the cytochrome bc(1) complex via interactions with the Rieske iron-sulfur protein and cytochrome b in the ubiquinol oxidation pocket. [2]
In vivo: Atovaquone is a unique naphthoquinone with broad-spectrum antiprotozoal activity. It is effective for the treatment and prevention of Pneumocystis carinii pneumonia (PCP), it is effective in combination with proguanil for the treatment and prevention of malaria, and it is effective in combination with azithromycin for the treatment of babesiosis. [3]
References:
[1] Looareesuwan S, et al. Am J Trop Med Hyg, 1996, 54(1), 62-66.
[2] Kessl JJ, et al. J Biol Chem, 2003, 278(33), 31312-31318.
[3] Aaron L, et al. Antimicrob Agents Chemother, 2002, 46(5), 1163-1173.